Depression News and Research

Latest Depression News and Research

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans™ (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days.

2 Jul 2010

Imbalance in neuroendocrine system linked to depression in MS patients: Study

Now, in the first such study in living humans, researchers at UCLA suggest a cause, and it's not psychological, but physical: atrophy of a specific region of the hippocampus, a critical part of the brain involved in mood and memory, among other functions.

2 Jul 2010

Does too much texting puts teenagers at risk?

A seemingly harmless method of communication - text messaging on mobile phones could damage teenagers physically and psychologically a new study has revealed.

1 Jul 2010

Hospira subsidiary completes tender offer for Javelin's outstanding shares of common stock

Hospira, Inc., a global specialty pharmaceutical and medication delivery company, today announced the successful completion of the tender offer by Discus Acquisition Corporation, a wholly owned Hospira subsidiary, to purchase all outstanding shares of the common stock of Javelin Pharmaceuticals, Inc..

1 Jul 2010

AstraZeneca announces new support program for patients on ARIMIDEX

AstraZeneca today announced a new patient support program for postmenopausal women with hormone receptor-positive early breast cancer who are prescribed ARIMIDEX. The program is designed to provide eligible patients with instant discounts, potentially saving the patient up to $300.

1 Jul 2010

Aptuit to acquire GSK's research business in Verona

GlaxoSmithKline (GSK) and Aptuit, Inc. announced today that they have finalized an agreement for Aptuit to acquire operations at GSK's Medicines Research Centre in Verona, Italy. The arrangement, which is effective as of July 1, 2010, provides for ongoing employment of the staff at the centre and for Aptuit to supply GSK with R&D services from the facilities. Financial terms have not been disclosed.

1 Jul 2010

Euthymics and DOV sign merger agreement

Euthymics Bioscience, Inc., a privately held Delaware corporation, and DOV Pharmaceutical, Inc., a Delaware corporation currently traded on the Pink Sheets, today jointly announced that they have signed a merger agreement in connection with the pending merger and acquisition of DOV by Euthymics.

1 Jul 2010

First analyses on impact of Medicare Part D presented at UMB's 2010 Academy/Health Annual Meeting

Some of the first analyses on the impact of Medicare Part D, as well as new insights on drug adherence patterns by chronic disease patients, will be presented today and tomorrow at the 2010 Academy/Health Annual Meeting by several University of Maryland, Baltimore teams of pharmaceutical health services researchers.

1 Jul 2010

Evotec commences EVT 101 proof-of-concept Phase II study in treatment-resistant depression

Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. This clinical development is part of an alliance between Evotec and Roche.

1 Jul 2010

Studies link anti-cholesterol statin drugs to increased risk of anxiety and depression

Scientists are reporting a possible explanation for the symptoms of anxiety and depression that occur in some patients taking the popular statin family of anti-cholesterol drugs, and reported by some individuals on low-cholesterol diets. These symptoms could result from long-term, low levels of cholesterol in the brain, the report suggests. It appears in ACS' weekly journal Biochemistry.

1 Jul 2010

Neuralstem announces completion of $10 million registered direct offering

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.

1 Jul 2010

Focus shifts to mental health policies

According to Health Minister Nicola Roxon, the Coalition has gone “crazy” for providing funds to promote its mental health policy by closing down the Labour health reforms in general practice and record keeping.

1 Jul 2010

Blue Shield of California offers SilverSneakers Fitness Program to Medicare Supplement Plan subscribers

Blue Shield of California is now offering the Healthways SilverSneakers® Fitness Program to subscribers of Blue Shield Medicare Supplement Plans throughout California. SilverSneakers, the nation's leading social support and exercise program designed to keep seniors healthy, has been a popular benefit with California Medicare HMOs, but Blue Shield is one of the few health plans in the state to offer the benefit as part of its Medicare Supplement plans as well.

30 Jun 2010

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

New long term data showed that Vimpat- (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy. In addition post-hoc exploratory analyses showed that adjunctive lacosamide treatment reduced partial-onset seizure frequency and improved responder rates when added to a broad range of antiepileptic drugs (AEDs) including both traditional sodium channel-blocking agents and those that act on non-sodium channel-targets.

30 Jun 2010

New hope for patients with drug-resistant depression

New research shows that a unique strain of laboratory mice characterized at Penn State University has behavioral, hormonal, and neurochemical characteristics that are similar to those of human patients with drug-resistant forms of depression.

30 Jun 2010

FDA grants approval for first generic version of Effexor XR antidepressant capsules

On June 28, the U.S. Food and Drug Administration approved the first generic version of Effexor XR capsules (venlafaxine hydrochloride) to treat major depressive disorder.

30 Jun 2010

Teenage girls more likely to perceive potential benefits of drug and alcohol use

Survey data released today by the Partnership for a Drug-Free America® and MetLife Foundation found that teenage girls are more likely than teenage boys to perceive potential benefits from drug use and drinking, making teen girls more vulnerable to drug and alcohol abuse.

29 Jun 2010

Depression News and Research

Latest Depression News and Research

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

Imbalance in neuroendocrine system linked to depression in MS patients: Study

Does too much texting puts teenagers at risk?

Hospira subsidiary completes tender offer for Javelin's outstanding shares of common stock

AstraZeneca announces new support program for patients on ARIMIDEX

Aptuit to acquire GSK's research business in Verona

Euthymics and DOV sign merger agreement

First analyses on impact of Medicare Part D presented at UMB's 2010 Academy/Health Annual Meeting

Evotec commences EVT 101 proof-of-concept Phase II study in treatment-resistant depression

Studies link anti-cholesterol statin drugs to increased risk of anxiety and depression

Neuralstem announces completion of $10 million registered direct offering

Focus shifts to mental health policies

Blue Shield of California offers SilverSneakers Fitness Program to Medicare Supplement Plan subscribers

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

New hope for patients with drug-resistant depression

FDA grants approval for first generic version of Effexor XR antidepressant capsules

Teenage girls more likely to perceive potential benefits of drug and alcohol use

Adolescent girls who perceive being overweight are more likely to feel depressed

Researchers study mechanism of human brain

Combination therapy for severe depression

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Depression News and Research

Latest Depression News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in